Xencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of Bispecific Oncology Pipeline at R&D Day -- Commenced multi-dose part of Phase 1a trial of XmAb®7195 examining IgE reduction and safety profile --- Study with subcutaneous formulation of XmAb7195 to begin in 2016 --- XmAb®13676 named as second XmAb® bispecific clinical candidate for development in B-cell malignancies -

MONROVIA, Calif., June 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. Updates are being presented today at its R&D Day for analysts and investors in New York, NY. "We are happy to report on the progress and expansion of our proprietary pipeline of XmAb antibodies," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "Today we will discuss the...